Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Comparative Study of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4
Brief Summary: Genotype 4 hepatitis C virus is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in the world. Although rare in western nations, genotype 4 is the most common variant of the hepatitis C virus in Egypt and is also found throughout Africa and the Middle East. Early reports on the treatment of patients with genotype 4 chronic hepatitis C with interferon-alfa (IFN)-alfa monotherapy indicate poor rates of sustained viral response (SVR). With the introduction of ribavirin combination therapy and with pegylation of the IFN alfa molecule, however, response rates have improved dramatically, and current clinical trial data indicate that SVR rates between 43 and 79% are attainable in genotype 4 patients who are receiving pegylated IFN alfa plus ribavirin for 48 weeks. Clinical advances to optimize treatment for each patient have also been made, and tailored treatment options are now being developed that are comparable to the treatment approaches for genotype 1, 2, and 3 patients. A treatment duration of between 36 and 48 weeks appears to be optimal for most patients with chronic hepatitis C genotype 4.The aim of this study is to assess the efficacy and safety of pegylated interferon alpha 2a in patients with chronic hepatitis C genotype 4 in comparison to a historical cohort of patients treated with pegylated interferon alpha 2b


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated interferon alpha 2a, Drug: Ribavirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated interferon alpha 2 b plus ribavirin | Intervention Type: DRUG; Name: Pegylated interferon alpha 2a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pegylated interferon alpha 2 b plus ribavirin; Assigned to Arm(s): 2
B: Arm Label: PegIntron 1.5 ug/kg/wk plus REBETOL; Type: EXPERIMENTAL; Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031), Drug: REBETOL (ribavirin; SCH 18908) | Arm Label: PegIntron 1.0 ug/kg/wk plus REBETOL; Type: EXPERIMENTAL; Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031), Drug: REBETOL (ribavirin; SCH 18908) | Arm Label: PEGASYS 180 ug/wk Plus COPEGUS; Type: ACTIVE_COMPARATOR; Interventions: Biological: PEGASYS (peginterferon alfa-2a), Drug: COPEGUS (ribavirin) | Intervention Type: BIOLOGICAL; Name: PegIntron (peginterferon alfa-2b; SCH 54031); Assigned to Arm(s): PegIntron 1.5 ug/kg/wk plus REBETOL | Intervention Type: BIOLOGICAL; Name: PegIntron (peginterferon alfa-2b; SCH 54031); Assigned to Arm(s): PegIntron 1.0 ug/kg/wk plus REBETOL | Intervention Type: DRUG; Name: REBETOL (ribavirin; SCH 18908); Assigned to Arm(s): PegIntron 1.0 ug/kg/wk plus REBETOL, PegIntron 1.5 ug/kg/wk plus REBETOL | Intervention Type: BIOLOGICAL; Name: PEGASYS (peginterferon alfa-2a); Assigned to Arm(s): PEGASYS 180 ug/wk Plus COPEGUS | Intervention Type: DRUG; Name: COPEGUS (ribavirin); Assigned to Arm(s): PEGASYS 180 ug/wk Plus COPEGUS
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a + Ribavirin, Drug: Peginterferon alfa-2a | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a + Ribavirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): 1
D: Arm Label: Peginterferon Alfa-2a + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Peginterferon alfa-2a [Pegasys] | Arm Label: Peginterferon Alfa-2b + Ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2b (PEG-Intron), Drug: Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Peginterferon Alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2b (PEG-Intron); Assigned to Arm(s): Peginterferon Alfa-2b + Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Peginterferon Alfa-2b + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a [Pegasys]; Assigned to Arm(s): Peginterferon Alfa-2a + Ribavirin

Answer: A